Home LiteratureArticle Details
PMID: 17530704 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.

Arthritis and rheumatism ·Vol. 56 ·No. 6 ·2007-06-00 ·Pages 1754-64

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH

Abstract

To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care. This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease-modifying antirheumatic drugs (DMARDs) were initiated. Patients were Medicare beneficiaries ages 65 years and older (mean age 76.5 years) who were concurrently enrolled in the Pharmaceutical Assistance Contract for the Elderly provided by the state of Pennsylvania. A total of 15,597 RA patients in whom a DMARD was initiated between January 1, 1995 and December 31, 2003 were identified using linked data on all prescription drug dispensings, physician services, and hospitalizations. Initiation of anti-TNFalpha therapy, cytotoxic agents other than methotrexate (MTX), noncytotoxic agents, and glucocorticoids was compared with initiation of MTX. The main outcome measure was serious bacterial infections that required hospitalization. The incidence of serious bacterial infections was, on average, 2.2 per 100 patient-years in this population (95% confidence interval [95% CI] 2.0-2.4). Glucocorticoid use doubled the rate of serious bacterial infections as compared with MTX use, independent of previous DMARD use (rate ratio [RR] 2.1 [95% CI 1.5-3.1]), with a clear dose-response relationship for dosages >5 mg/day (for < or = 5 mg/day, RR 1.34; for 6-9 mg/day, RR 1.53; for 10-19 mg/day, RR 2.97; and for > or = 20 mg/day, RR 5.48 [P for trend < 0.0001]). Adjusted models showed no increase in the rate of serious infections among initiators of anti-TNFalpha therapy (RR 1.0 [95% CI 0.6-1.7]) or other DMARDs as compared with initiators of MTX. In a large cohort of patients with RA, we found no increase in serious bacterial infections among users of anti-TNFalpha therapy compared with users of MTX. Glucocorticoid use was associated with a dose-dependent increase in such infections.

MeSH Terms
Adalimumab Aged Aged, 80 and over Antibodies, Monoclonal/adverse effects,therapeutic use Antibodies, Monoclonal, Humanized Antirheumatic Agents/adverse effects,therapeutic use Arthritis, Rheumatoid/drug therapy,microbiology,physiopathology Bacterial Infections/chemically induced,physiopathology Cohort Studies Dose-Response Relationship, Drug Etanercept Female Glucocorticoids/adverse effects,therapeutic use Humans Immunoglobulin G/adverse effects,therapeutic use Incidence Infliximab Male Methotrexate/adverse effects,therapeutic use Poverty Receptors, Tumor Necrosis Factor/therapeutic use Risk Factors Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antirheumatic Agents Glucocorticoids Immunoglobulin G Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Infliximab Adalimumab Etanercept Methotrexate
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schneeweiss Sebastian
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA. [email protected]
Setoguchi Soko
Weinblatt Michael E
Katz Jeffrey N
Avorn Jerry
Sax Paul E
Levin Raisa
Solomon Daniel H
Article Info
Journal
Arthritis and rheumatism
Abbr.
Arthritis Rheum
ISSN
0004-3591
Published
2007-06-00
Pages
1754-64
Language
English
Region
United States
NLM ID
0370605
Subset
IM
Grants
NIAMS NIH HHS · K23-AR-48616 · United States
NIAMS NIH HHS · K24-AR-02123 · United States
NIAMS NIH HHS · P60-AR-47782 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]